MK-571 (L-660,711): Mechanisms and Applications in Inflammation and Resistance

Executive Summary: MK-571 (L-660,711) is a high-affinity, orally active antagonist of the leukotriene D4 (LTD4) receptor, also known as cysLT1. It competitively inhibits LTD4 and LTE4 binding, blocking smooth muscle contraction and vascular permeability increases (product information). With nanomolar Ki values in lung membranes and pA2 values up to 10.5 in tracheal assays, its utility extends to bronchoconstriction and allergic pulmonary inflammation models. MK-571 also inhibits the multidrug resistance protein 1 (MRP1/ABCC1), impacting immune cell protection in drug exposure scenarios (Qiao et al., 2026). This duality supports advanced research in inflammation, asthma, and resistance mechanisms, as detailed in recent literature and APExBIO protocols.

Biological Rationale

Leukotriene D4 (LTD4) and LTE4 are key mediators of bronchoconstriction and vascular permeability, driving symptoms in asthma and allergic pulmonary inflammation (see mechanistic overview). The cysLT1 receptor is a validated pharmacological target for controlling these responses. In parallel, the multidrug resistance protein MRP1 (ABCC1) contributes to immune cell survival under chemotherapeutic stress by mediating drug efflux and regulating glutathione (GSH) homeostasis. MK-571 (L-660,711) inhibits both pathways, enabling researchers to dissect leukotriene-mediated inflammation and to explore mechanisms of resistance and immune cell protection. This dual action makes it instrumental in both pulmonary and immunological research models (LPS-macrophage study).

Mechanism of Action of MK-571 (L-660,711) leukotriene D4 receptor antagonist

MK-571 acts as a competitive, selective antagonist at the cysLT1 receptor (LTD4 receptor), blocking the binding of LTD4 and LTE4. This inhibits downstream signaling that leads to bronchial smooth muscle contraction and increased vascular permeability (APExBIO product info). The compound’s Ki is 0.22 nM in guinea pig lung and 2.1 nM in human lung membranes, demonstrating high receptor affinity. In functional assays, it blocks LTD4- and LTE4-induced contractions in guinea pig and human trachea (pA2: 8.5–10.5). Independently, MK-571 inhibits ABCC1 (MRP1), a transporter critical for GSH efflux and drug resistance. This action modulates IL-6 production in activated monocytic cells and impacts macrophage viability in the context of drug exposure (Qiao et al., 2026). The dual mechanism underpins its versatility in both inflammation and resistance research (mechanistic review).

Evidence & Benchmarks

• MK-571 exhibits a Ki of 0.22 nM in guinea pig and 2.1 nM in human lung membranes, confirming high-affinity cysLT1 antagonism (APExBIO).
• Blocks LTD4/LTE4-induced contraction in guinea pig trachea and ileum, and human trachea, with pA2 values from 8.5 to 10.5 (APExBIO).
• Reduces eosinophil and neutrophil infiltration and lung microvascular leakage in animal models of pulmonary inflammation (APExBIO).
• Inhibits ABCC1, reducing GSH-mediated protection of macrophages from antitumor drugs in vitro and in vivo (Qiao et al., 2026).
• In LPS-treated RAW264.7 macrophages, MK-571 suppresses LPS-induced upregulation of SLC7A11 and intracellular GSH, lowering cell viability under drug challenge (Qiao et al., 2026).
• MK-571 is soluble at ≥55.1 mg/mL in DMSO, but insoluble in ethanol and water, supporting high-concentration stock solutions (APExBIO).

This article extends the practical perspective of MK-571 for Immune Cell Viability by integrating new mechanistic data on GSH modulation and ABCC1 transport.

Applications, Limits & Misconceptions

MK-571 (L-660,711) is widely used in asthma research, allergic pulmonary inflammation models, and the study of leukotriene-mediated inflammation. Its ability to inhibit ABCC1/ MRP1 also makes it valuable for investigating multidrug resistance mechanisms and immune cell protection under chemotherapeutic conditions. The compound is a research tool, not a therapeutic, and should not be used in clinical protocols. Recent studies confirm its efficacy in dissecting the molecular crosstalk between leukotriene signaling and drug efflux pathways (assay optimization article).

Common Pitfalls or Misconceptions

• MK-571 is not selective for all leukotriene receptors; its primary affinity is for cysLT1, not cysLT2.
• It does not inhibit all multidrug resistance proteins—its action is specific to ABCC1/MRP1, not P-gp (ABCB1) or BCRP.
• Solubility is limited to DMSO; attempts in ethanol or water are ineffective and may cause precipitation.
• MK-571 is for research use only and is not validated for therapeutic or diagnostic purposes in humans.
• Long-term storage of solutions above -20°C can result in degradation and loss of activity.

Workflow Integration & Parameters

• Stock solution preparation: Dissolve at ≥55.1 mg/mL in DMSO; apply warming or ultrasonic treatment for full dissolution (APExBIO).
• Storage: Solid at -20°C; DMSO stock solutions below -20°C are stable for several months.
• Cell culture use: Use DMSO-diluted MK-571 at working concentrations typically 1–20 μM; avoid ethanol or aqueous dilution.
• In vivo models: Administer orally; dosing regimens and vehicle should be empirically optimized per model.
• Functional assays: For LTD4/LTE4 antagonism, pre-incubate tissues or cells 15–30 min before agonist challenge.
• MRP1 inhibition: Use in combination with LPS or chemotherapeutic agents to probe macrophage protection mechanisms (Qiao et al., 2026).

Conclusion & Outlook

MK-571 (L-660,711) remains a cornerstone reagent for dissecting leukotriene-mediated inflammation and multidrug resistance mechanisms. Its dual function as a cysLT1 antagonist and MRP1 inhibitor enables precise modeling of airway inflammation and immune cell survival under chemotherapeutic stress. Current evidence suggests that leveraging MK-571 in combination with established protocols, such as LPS-macrophage protection assays, yields mechanistic clarity and reproducible results. Future research may further elucidate its role in immune modulation and inform safer therapeutic strategies, as highlighted in recent mechanistic studies (Qiao et al., 2026).